Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Director Sells $345,400.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Stock Up 9.1%

ELVN opened at $40.36 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $48.53. The company has a fifty day moving average of $41.30 and a 200-day moving average of $30.62. The stock has a market cap of $2.46 billion, a PE ratio of -24.17 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ELVN. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Guggenheim began coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective for the company. Stifel Nicolaus began coverage on shares of Enliven Therapeutics in a research report on Tuesday. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $61.50.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. increased its stake in Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. KBC Group NV bought a new stake in Enliven Therapeutics during the 1st quarter valued at $38,000. Finally, Swiss National Bank increased its stake in Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.